This content is machine translated EHA in Stockholm CAR-T cells – New therapeutic approach for multiple myeloma There are new therapeutic approaches in multiple myeloma. For example, the efficacy and safety of CAR-T cells are being studied. In particular, they could be applicable in the refractory and…
View Post 7 min This content is machine translated Therapy for initial diagnosis of multiple myeloma Treatment protocols in the age of modern substances We are in the era of new efficient compounds against multiple myeloma. Nevertheless, high-dose chemotherapy followed by autologous stem cell transplantation remains an essential part of the first-line treatment of…
View Post 5 min This content is machine translated ASH 2016 in San Diego Multiple Myeloma Review As every year, the ASH Congress took place in the busy pre-Christmas season. This time, experts from hematology and oncology met in San Diego. Multiple myeloma was again an important…
View Post 6 min This content is machine translated Oncology Annual Congress in Basel Risk- and age-adapted approach to multiple myeloma In October, the annual congress of the German, Austrian and Swiss Societies of Hematology and Medical Oncology was held in Basel. A scientific symposium focused on risk- and age-adapted management…
View Post 4 min This content is machine translated Mantle cell lymphoma First- and second-line lenalidomide Mantle cell lymphoma (MZL) is an aggressive non-Hodgkin’s lymphoma that accounts for approximately 3-6% of all NHL cases. It has a poor prognosis, especially after failure of first-line therapy. Lenalidomide…
View Post 5 min This content is machine translated Multiple Myeloma “Myeloma therapy has made great strides in recent years” In an interview with InFo ONCOLOGY & HEMATOLOGY, Prof. Christoph Renner, MD, Onkozentrum Hirslanden, Zurich, discusses the latest therapeutic advances in multiple myeloma. In doing so, he answers questions such…
View Post 4 min This content is machine translated Multiple Myeloma Active ingredients at a glance At the EHA Congress in Milan, multiple myeloma was the focus of several events. What are the current results of proteasome inhibitors and immunomodulatory drugs and what is their promise…
View Post 3 min This content is machine translated Newly diagnosed multiple myeloma Does a proteasome inhibitor offer new therapeutic options? One study discussed at the ASH meeting involved a regimen consisting of oral MLN9708 administered twice weekly plus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. It concludes…
View Post 2 min This content is machine translated Multiple Myeloma Media Workshop Which form of therapy is suitable for whom? At a media workshop during the ASH Congress in New Orleans, some key points of myeloma research were presented. They also discussed what these innovations mean for patients and used…
